Lazard Asset Management
CRMD icon

Lazard Asset Management’s CorMedix CRMD Stock Holding History

Lazard Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,000
Closed -$930K – 1916
2025
Q4 		$930K Buy
+80,000
New +$884K ﹤0.01% 1177

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lazard Asset Management's CRMD Position: Q2 2026 in Review

Lazard Asset Management reduced its CorMedix (CRMD) stake by 92% in Q2 2026, selling an estimated $1.76M and leaving 20,000 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Lazard Asset Management first reported a position in CRMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.16M in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Lazard Asset Management held 20,000 shares of CorMedix worth $157K as of Q2 2026.
  • Lazard Asset Management sold 223,179 CorMedix shares in Q2 2026, an estimated $1.76M.
  • CorMedix made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1708 holding.
  • Lazard Asset Management first reported a position in CorMedix in Q4 2025 and has held it in 3 quarters since.
  • Lazard Asset Management's CorMedix position peaked at $3.16M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.